2DG and glycolysis as therapeutic targets for status epilepticus.
Saved in:
| Title: | 2DG and glycolysis as therapeutic targets for status epilepticus. |
|---|---|
| Authors: | Sutula TP; Department of Neurology, University of Wisconsin, Madison, WI, USA; Hexokine Therapeutics, Inc., Madison, WI, USA. Electronic address: sutula@neurology.wisc.edu., Fountain NB; Department of Neurology, F.E. Dreifuss Comprehensive Epilepsy Program, University of Virginia, Charlottesville, VA, USA; Hexokine Therapeutics, Inc., Madison, WI, USA. |
| Source: | Epilepsy & behavior : E&B [Epilepsy Behav] 2023 Mar; Vol. 140, pp. 109108. Date of Electronic Publication: 2023 Feb 16. |
| Publication Type: | Journal Article; Review; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. |
| Journal Info: | Publisher: Academic Press Country of Publication: United States NLM ID: 100892858 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-5069 (Electronic) Linking ISSN: 15255050 NLM ISO Abbreviation: Epilepsy Behav Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1525-5069 |
|---|---|
| DOI: | 10.1016/j.yebeh.2023.109108 |
